in V 2-5 leads, and ST-segment depression in II, III and aVF. The patient was immediately transferred to a catheterization laboratory, where coronary angiography was performed, which showed a dominant right coronary artery with no significant stenosis, acute occlusion of the left anterior descending artery and chronic occlusion of the intermediate branch. Primary percutaneous coronary intervention (PCI) with implantation of an Integrity bare metallic stent (Medtronic Cardiovascular, Santa Rosa, CA, USA) 3.0×1.2 mm into the left anterior descending artery was performed, resulting in complete reperfusion { Thrombolysis in Myocardial Infarction (TIMI) 3 flow } . Intravascular ultrasound was not performed during the procedure. Initial echocardiography revealed a 1.65×1.55 cm blood clot, fixed in an area near the apical part of the left ventricle (LV). His total cholesterol was 4.29 mmol/L, low density lipoproteincholesterol (LDL-C) 2.7 mmol/L and triglycerides 1.37 mmol/L and estimated glomerular filtration rate was >60 mL/min/ 1.73. The patient was prescribed aspirin 75 mg, clopidogrel 75 mg, enoxaparin 60 mg, ramipril 2.5 mg, nebivolol 2.5 mg and atorvastatin 40 mg. Because of the retroviral infection, he had been receiving combined antiretroviral therapy (cART) for 6 years. The cART regiment consistied of 2 nucleoside reverse transcriptase inhibitors (emtricitabine and tenofovir), and protease inhibitor lopinavir boosted with ritonavir (lopinavir/r). His plasma HIV ribonucleic acid (RNA) levels, measured by real-time polymerase chain reaction were undetectable. The counts of T lymphocytes CD4 and CD8 were 625 cells/µL (norm, 410-1590 cells/µL) and 818 cells/µL (norm, 190-1140 cells/µL), respectively. The CD4/CD8 ratio was 0.76. After 5 days of hospitalization, he was discharged and instructed to continue the prescribed medications.
Two weeks after discharge, the patient was readmitted to the hospital because of general fatigue and malaise. Full examination did not reveal any abnormalities other than the previously described blood clot in LV. The patient was discharged and referred for ambulatory surveillance by a cardiologist when his coagulation parameters including the activated partial thromboplastin time (aPTT) were in the normal range. After 10 days (37 days from the first hospitalization), the patient again presented to the hospital with acute chest pain. His troponin I level was 4.74 ng/mL, and in the ECG, a QS complex was seen in leads V 1-3, with new ST-segment elevation. With an initial diagnosis of type 4b myocardial infarction (MI) (Table 1), the patient again underwent coronary angiography, which showed acute occlusion of the left anterior descending artery because of in-stent thrombosis. After a bolus of eptifibatide, the thrombus was aspirated with good hemodynamic results (TIMI 3 flow). Follow up echocardiography showed a change in the diameter of the clot in the LV (from 1.65×1.55 cm to 2.2×1.2 cm), and akinesis of the apex, a part of the intraventricular septum, and the anterior wall, with an ejection fraction of 33%. Due to the thrombosis, platelet function tests were performed. The aspirin reaction unit was 394, and the P2Y12 reaction unit was 155. At this time, his total cholesterol was 2.8 mmol/L, LDL-C 1.4 mmol/L and triglycerides 1.7 mmol/L. The patient was prescribed aspirin 75 mg, prasugrel 10 mg, carvedilol 25 mg, torasemide 5 mg, ramipril 2.5 mg, spironolactone 12.5 mg, atorvastatin 40 mg and warfarin (to keep the INR at 2.5). A modification of the cART regimen was introduced. The patient still received the combination of emtricitabine and tenofovir, but the protease inhibitor was changed from lopinavir/r to darunavir/r. After 6 months of follow-up, the patient is in good general condition, with undetectable HIV RNA levels and no drop of T helper lymphocytes CD4.
Discussion
In taking care of patients after an MI, we have to take into consideration the patient's co-morbidities and modify the treatment accordingly. In our patient's case, during the first MI, he received the proper treatment including double antiplatelet therapy that consisted of aspirin and a P2Y12 inhibitor, clopidogrel, along with enoxaparin, a low molecular weight heparin. Nevertheless, only after 1.5 months, the patient suffered another major adverse cardiac event due to in-stent thrombosis. Referring to the newest universal definition of MI developed in 2012 by the European Society of Cardiology, we diagnosed the patient with MI type 4b, which covers MI related to stent thrombosis, which was detected in our case by coronary angiography.
1) After the second event, the patient was prescribed 2) The alteration in the antiplatelet therapy was important because of the increased risk of cardiovascular disease and hypercoagulation, which our patient was exposed to through his co-morbidities.
For not yet fully disclosed reasons, patients with HIV infection suffer from a large number of non-AIDS conditions. cART prolongs life but does not fully restore health. Both, HIV and antiretroviral treatment increase the risk of development of conditions such as kidney and liver dysfunction, cancer, osteoporosis, neurological diseases and other end-organ diseases. HIV-positive patients are also known to not only have a shorter life-expectancy, but also to face accelerated aging.
3) One of the biggest concerns in this group of patients is diseases of the cardiovascular system. cART therapy is known to cause endothelial dysfunction and alterations in the lipid profile (including elevated triglyceride levels, a high proportion of small and dense LDL particles, and low high density lipoproteincholesterol levels), leading to an increased risk of MI. 
10)
Today a cardiologist rarely deals with a patient afflicted only with an isolated disease of the heart or vessels. Due to prolonged life expectancy, our patients are more and more often burdened with many comorbidities. Now we have to deal with not only diseases related to the fields of cardionephrology, cardiodiabetology, cardiosexology, cardiooncology, but also diseases in other fields like the combination of cardiology with infectious diseases. It is important to remember to look at the whole patient instead of only the heart. There is a need for close cooperation between a cardiologist and doctors of other fields, with an expansion of the Heart Team concept to everyday practice. Cardiologists rarely deal with HIV-infected patients and often do not have much knowledge of cART interactions, so that every time a new drug is added to a patient's regimen, it can be helpful to consult with an infectious diseases specialist.
